Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) clinical trial (NCT07488923). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential risks and side effects of ML261 compared to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) clinical trial (NCT07488923). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) clinical trial (NCT07488923). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or complications during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) clinical trial (NCT07488923). Contact the study team or your healthcare provider for specific answers.

Question 5

How long will I need to participate in the trial, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) clinical trial (NCT07488923). Contact the study team or your healthcare provider for specific answers.

Question 6

What support will be available to me during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) clinical trial (NCT07488923). Contact the study team or your healthcare provider for specific answers.

What this study is about